These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 11267150)

  • 1. Donor pretreatment of grafts from marginal donors improves long-term graft outcome.
    Reutzel-Selke A; Tullius SG; Zschockelt T; Nieminen-Kelhä M; Bachmann U; Jonas S; Pratschke J; Schmidbauer G; Bechstein WO; Volk H; Neuhaus P
    Transplant Proc; 2001; 33(1-2):970-1. PubMed ID: 11267150
    [No Abstract]   [Full Text] [Related]  

  • 2. Short-term immunosuppressive treatment of the donor ameliorates consequences of ischemia/ reperfusion injury and long-term graft function in renal allografts from older donors.
    Reutzel-Selke A; Zschockelt T; Denecke C; Bachmann U; Jurisch A; Pratschke J; Schmidbauer G; Volk HD; Neuhaus P; Tullius SG
    Transplantation; 2003 Jun; 75(11):1786-92. PubMed ID: 12811235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of various immunosuppressive drugs in preventing pig-to-rat islet xenograft rejection.
    Wennberg L; Wallgren AC; Karlsson-Parra A; Kozlowski T; Sundberg B; Tibell A; Groth CG; Korsgren O
    Transplant Proc; 1995 Feb; 27(1):266-7. PubMed ID: 7533391
    [No Abstract]   [Full Text] [Related]  

  • 4. Late subcapsular lymphocele in a kidney graft.
    Mestres J; Sebastià C; Musquera M; Paño B; Peri L; Alcaraz A; Nicolau C
    Transplantation; 2012 Apr; 93(8):e35-7. PubMed ID: 22487814
    [No Abstract]   [Full Text] [Related]  

  • 5. Substantial proliferation of human renal tubular epithelial cell-reactive CD4+CD28null memory T cells, which is resistant to tacrolimus and everolimus.
    Demmers MW; Baan CC; Janssen M; Litjens NH; Ijzermans JN; Betjes MG; Weimar W; Rowshani AT
    Transplantation; 2014 Jan; 97(1):47-55. PubMed ID: 24157471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Onset of liver regeneration after subtotal resection is inhibited by the use of new immunosuppressive drugs.
    Dahmen U; Gu Y; Shen K; Dirsch O; Li J; Fan L; Broelsch C
    Transplant Proc; 2002 Sep; 34(6):2312-3. PubMed ID: 12270412
    [No Abstract]   [Full Text] [Related]  

  • 7. Everolimus-treated renal transplant recipients have a more robust CMV-specific CD8+ T-cell response compared with cyclosporine- or mycophenolate-treated patients.
    Havenith SH; Yong SL; van Donselaar-van der Pant KA; van Lier RA; ten Berge IJ; Bemelman FJ
    Transplantation; 2013 Jan; 95(1):184-91. PubMed ID: 23222818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apoptosis and treatment of chronic allograft nephropathy with everolimus.
    Lutz J; Zou H; Liu S; Antus B; Heemann U
    Transplantation; 2003 Aug; 76(3):508-15. PubMed ID: 12923436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of everolimus and tacrolimus in kidney transplant patients with intolerance to mycophenolate mofetil/mycophenolic acid.
    Balda S; Inza A; Odriozola N; Zárraga S; García-Erauskin G; Lampreabe I
    Transplant Proc; 2009; 41(6):2095-8. PubMed ID: 19715841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sirolimus protective effects on bone: the need to be demonstrated.
    Luo LM; Wang LL
    Nephrol Dial Transplant; 2012 Jun; 27(6):2602-3. PubMed ID: 22323528
    [No Abstract]   [Full Text] [Related]  

  • 11. The effect of differing immunosuppressive regimes on the functional and morphologic changes in a rat renal allograft model of chronic rejection.
    McGrath JS; Shehata M
    Transplant Proc; 2001 May; 33(3):2191-2. PubMed ID: 11377499
    [No Abstract]   [Full Text] [Related]  

  • 12. Immunosuppressive treatment and progression of histologic lesions in kidney allografts.
    Morales JM
    Kidney Int Suppl; 2005 Dec; (99):S124-30. PubMed ID: 16336565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
    Favi E; Spagnoletti G; Salerno MP; Pedroso JA; Romagnoli J; Citterio F
    Clin Transplant; 2013; 27(4):E359-67. PubMed ID: 23710603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of different immunosuppressants on alloantigen dependent and independent factors involved in the development of chronic rejection in an animal model.
    Cole O; Rigg K; Shehata M
    Ann R Coll Surg Engl; 2001 Jul; 83(4):235-43. PubMed ID: 11518369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of RS61443 on chronic rejection of rat kidney allografts.
    Azuma H; Binder J; Heemann U; Tullius SG; Tilney NL
    Transplant Proc; 1995 Feb; 27(1):436-7. PubMed ID: 7879052
    [No Abstract]   [Full Text] [Related]  

  • 16. RAD reduces compensatory renal graft hypertrophy in a rat model of chronic rejection.
    Viklický O; Müller V; Zou H; Szabó A; Vitko S; Heemann U
    Transplant Proc; 2001 May; 33(3):2320-1. PubMed ID: 11377546
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacodynamics of the immunosuppressive effects of the combination of tacrolimus with mycophenolate mofetil.
    Barten MJ; Rahmel A; Richter M; Tarnok A; Bartsch P; Boeger M; Gehlhaar P; Dhein S; Mohr FW; Gummert JF
    Transplant Proc; 2002 Sep; 34(6):2372-3. PubMed ID: 12270442
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of commonly used immunosuppressants on graft-derived fibroblasts.
    Johnsson C; Gerdin B; Tufveson G
    Clin Exp Immunol; 2004 Jun; 136(3):405-12. PubMed ID: 15147341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined immunosuppression with cyclosporine, rapamycin, and mycophenolate mofetil controls rejection with minimal nutritional impact in experimental small intestinal transplantation.
    Sigalet DL; Thorne PC; Martin GR; Garola RE; Yatscoff RW
    Transplant Proc; 2002 Jun; 34(4):1121-3. PubMed ID: 12072293
    [No Abstract]   [Full Text] [Related]  

  • 20. Does tacrolimus, in comparison with sirolimus, increase mycophenolic acid exposure in kidney transplant recipients?
    Picard N
    Clin Pharmacol Ther; 2010 Jun; 87(6):650-1. PubMed ID: 20393455
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.